Employing PSI™ to Identify Optimal Bi-Specific Antibody Candidates

Learn how PSI can help you reveal functional immune-tumor interaction and mechanism of therapy to advise lead choice.

Unlock Resource
Download this free resource and gain access to our full resource library!

Unlock All Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.

fierce innovation award
red dot award winner
scientist award

Application of bispecific antibody constructs to improve immunotherapy success

Recent clinical progress in immunooncology significantly improved clinical outcomes for many patients with hard-to-treat malignant tumors, leading to partial and complete remission and long-term survival in a fraction of patients. However, a large number of patients do not respond to these treatments, creating an urgent need for novel strategies to enhance the efficacy of immunotherapies.

In this Application Highlight we discuss:
  • Highlight the use of IsoPlexis’ Polyfunctional Strength Index, PSI™, a single-cell cytokinebased metric of cellular potency, in the context of pre-clinical assessment of bispecific antibodies
  • Identify subtle differences in quality of novel bispecific antibody constructs relative to controls, utilizing the PSI of the potent T cell subsets engaged
  • Demonstrate that PSI can improve the choice of lead bispecific immunotherapeutic products by identifying key differences in the therapies’ cytokine-based mechanisms at the single-cell level